SI3715345T1 - Priprava zaviralca lfa-1 - Google Patents
Priprava zaviralca lfa-1Info
- Publication number
- SI3715345T1 SI3715345T1 SI201332083T SI201332083T SI3715345T1 SI 3715345 T1 SI3715345 T1 SI 3715345T1 SI 201332083 T SI201332083 T SI 201332083T SI 201332083 T SI201332083 T SI 201332083T SI 3715345 T1 SI3715345 T1 SI 3715345T1
- Authority
- SI
- Slovenia
- Prior art keywords
- lfa
- inhibitor
- preparation
- Prior art date
Links
- 102100022339 Integrin alpha-L Human genes 0.000 title 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675663P | 2012-07-25 | 2012-07-25 | |
| US201261680099P | 2012-08-06 | 2012-08-06 | |
| US201261729294P | 2012-11-21 | 2012-11-21 | |
| EP20153723.0A EP3715345B8 (en) | 2012-07-25 | 2013-07-25 | Preparation of lfa-1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3715345T1 true SI3715345T1 (sl) | 2024-07-31 |
Family
ID=49995472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201332083T SI3715345T1 (sl) | 2012-07-25 | 2013-07-25 | Priprava zaviralca lfa-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9085553B2 (enExample) |
| EP (3) | EP4406950A3 (enExample) |
| JP (3) | JP6607780B2 (enExample) |
| KR (2) | KR20200108932A (enExample) |
| CN (2) | CN104797574B (enExample) |
| AU (5) | AU2013295706A1 (enExample) |
| BR (1) | BR112015001608B1 (enExample) |
| CA (1) | CA2879982C (enExample) |
| HK (1) | HK1210782A1 (enExample) |
| IN (1) | IN2015DN00847A (enExample) |
| MX (2) | MX2015001098A (enExample) |
| RU (1) | RU2658015C2 (enExample) |
| SI (1) | SI3715345T1 (enExample) |
| WO (1) | WO2014018748A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2960117C (en) * | 2005-05-17 | 2018-01-30 | Sarcode Bioscience Inc. | Lfa-1 antagonists for the treatment of eye disorders |
| JP2011521896A (ja) * | 2008-04-15 | 2011-07-28 | サーコード コーポレイション | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
| WO2014018748A1 (en) * | 2012-07-25 | 2014-01-30 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
| AU2015320349B2 (en) * | 2014-09-25 | 2020-03-12 | Bausch + Lomb Ireland Limited | Continuous flow carboxylation reaction |
| CN113230021A (zh) | 2015-01-12 | 2021-08-10 | 科达莱昂治疗公司 | 微滴递送设备和方法 |
| CA3016546A1 (en) | 2016-03-04 | 2017-09-08 | James M. Rynerson | Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation |
| EP3492466B1 (en) * | 2016-07-29 | 2022-06-01 | Wuhan LL Science And Technology Development Co., Ltd. | Oral solid preparation and use thereof |
| EP3496662A4 (en) | 2016-08-12 | 2019-10-30 | Silk Technologies Ltd. | SILICONE PROTEIN FOR THE TREATMENT OF IGNITION |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| EP3570986B1 (en) | 2017-01-20 | 2025-03-19 | Bausch + Lomb Ireland Limited | Piezoelectric fluid dispenser |
| CN106947792A (zh) * | 2017-03-07 | 2017-07-14 | 上海倍殊生物科技有限公司 | 一种间甲砜基‑l‑苯丙氨酸的制备方法 |
| TWI681958B (zh) * | 2017-06-30 | 2020-01-11 | 台灣神隆股份有限公司 | 製備利非斯特及其中間體的方法 |
| WO2019020580A1 (en) | 2017-07-24 | 2019-01-31 | Interquim, S.A. | PROCESS FOR PREPARING AND PURIFYING LIFITEGRAST ANTAGONIST OF LFA-1 |
| US20200369652A1 (en) * | 2017-08-03 | 2020-11-26 | Dr. Reddy's Laboratories Limited | Processes for preparation of lifitegrast and intermediates thereof |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| BR112020006874A2 (pt) | 2017-10-10 | 2020-10-06 | Mankind Pharma Ltd. | processo inovador para a preparação de lifitegrast |
| WO2019097547A1 (en) * | 2017-11-15 | 2019-05-23 | Cipla Limited | An improved process for the preparation of lifitegrast or salts thereof |
| WO2019096996A1 (en) | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| US11278448B2 (en) | 2017-12-08 | 2022-03-22 | Kedalion Therapeutics, Inc. | Fluid delivery alignment system |
| KR20200105657A (ko) | 2018-01-15 | 2020-09-08 | 코그니보티스 에이비 | 산업용 로봇 아암 |
| US10435395B1 (en) | 2018-03-30 | 2019-10-08 | Scinopharm Taiwan, Ltd. | Crystal forms of lifitegrast |
| US11345683B2 (en) * | 2018-03-31 | 2022-05-31 | Aurobindo Pharma Ltd | Process for the preparation of lifitegrast |
| US20190314198A1 (en) | 2018-04-12 | 2019-10-17 | Kedalion Therapeutics, Inc. | Topical Ocular Delivery Methods and Devices for Use in the Same |
| US12350194B1 (en) | 2018-04-12 | 2025-07-08 | Bausch + Lomb Ireland Limited | Topical ocular delivery of fluids with controlled mass dosing and wireless communication |
| IT201800006337A1 (it) * | 2018-06-14 | 2019-12-14 | Procedimento per la preparazione di lifitegrast | |
| KR102827233B1 (ko) | 2018-07-03 | 2025-06-30 | 보슈 롬 아일랜드 리미티드 | 국소 안구 전달 디바이스들 및 이를 사용하기 위한 방법들 |
| CN111100118A (zh) * | 2018-10-29 | 2020-05-05 | 重庆圣华曦药业股份有限公司 | 一种立他司特杂质及其制备方法 |
| CN109384717A (zh) * | 2018-10-29 | 2019-02-26 | 广安凯特制药有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酸盐酸盐水合物及其制备方法和用途 |
| CN111285855A (zh) * | 2018-12-07 | 2020-06-16 | 苏州旺山旺水生物医药有限公司 | 一种制备化合物Lifitegrast的方法 |
| CN111471003B (zh) * | 2019-01-24 | 2022-09-23 | 上海皓元医药股份有限公司 | 一种立他司特中间体的制备方法 |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| US12097145B2 (en) | 2019-03-06 | 2024-09-24 | Bausch + Lomb Ireland Limited | Vented multi-dose ocular fluid delivery system |
| EP3955926A4 (en) | 2019-04-18 | 2022-11-30 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN110256343A (zh) * | 2019-05-28 | 2019-09-20 | 苏州芝宇生物科技有限公司 | 3,5-二氯-4-溴异喹啉衍生物及其制备方法和应用 |
| CN112409256B (zh) * | 2019-08-21 | 2024-04-02 | 山东福长药业有限公司 | 5,7-二氯四氢异喹啉缩醛胺类化合物、其制备方法与应用 |
| US12496218B1 (en) | 2019-11-12 | 2025-12-16 | Bausch + Lomb Ireland Limited | Fractionated topical ocular drug delivery methods and devices for use in the same |
| CN114980839B (zh) | 2019-11-15 | 2025-04-18 | 蚕丝科技有限公司 | 丝蛋白的稳定制剂 |
| CN111057003A (zh) * | 2019-12-06 | 2020-04-24 | 广安凯特制药有限公司 | 一种立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉的合成方法 |
| US12290472B2 (en) | 2020-04-17 | 2025-05-06 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| EP4120974A4 (en) | 2020-04-17 | 2024-05-22 | Bausch + Lomb Ireland Limited | HYDRODYNAMIC ACTUATED PRESERVATIVE-FREE DELIVERY SYSTEM |
| US12090087B2 (en) | 2020-04-17 | 2024-09-17 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir |
| CN111205275A (zh) * | 2020-04-22 | 2020-05-29 | 南京佰麦生物技术有限公司 | 立他司特晶型及其制备方法 |
| CN112321506B (zh) * | 2020-11-26 | 2021-12-24 | 江西天戌药业有限公司 | 一种5,7-二氯-1,2,3,4-四氢异喹啉的制备方法 |
| CN112500343B (zh) * | 2020-12-26 | 2023-04-07 | 山东金城柯瑞化学有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN112300139A (zh) * | 2020-12-29 | 2021-02-02 | 南京佰麦生物技术有限公司 | 立他司特水合物晶型及其制备方法 |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN113880819B (zh) * | 2021-09-18 | 2024-09-20 | 浙江大学医学院附属第一医院 | 立他司特的制备方法及其中间体化合物 |
| CN116063286A (zh) * | 2021-10-29 | 2023-05-05 | 威智医药有限公司 | 一种立他司特及其中间体的制备方法 |
| CN114524767B (zh) * | 2022-03-11 | 2022-10-18 | 成都道合尔医药技术有限公司 | 立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN115784950B (zh) * | 2022-12-08 | 2024-06-28 | 广东先强药业有限公司 | 一种立他司特中间体的制备方法 |
| CN116239532B (zh) * | 2022-12-19 | 2023-11-07 | 浙江博崤生物制药有限公司 | 一种二氯四氢异喹啉羧酸的中间体及其制备方法和应用 |
| CN116462644B (zh) * | 2023-05-06 | 2024-11-19 | 上海华默西医药科技有限公司 | 一种2-(呋喃-2-基亚甲基)-4-硝基丁酸酯化合物及其制备方法和应用 |
| WO2025186765A1 (en) * | 2024-03-08 | 2025-09-12 | Olon S.P.A. | Process for preparing lifitegrast |
| WO2025186758A1 (en) * | 2024-03-08 | 2025-09-12 | Olon S.P.A. | Process for preparing lifitegrast |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5759843A (en) * | 1980-09-30 | 1982-04-10 | Neos Co Ltd | Perfluoroalkyl ether amide derivative and its preparation |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| EP0314863B1 (en) | 1987-11-02 | 1994-12-07 | Baylor College Of Medicine | Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation |
| EP0326151B1 (en) | 1988-01-29 | 1993-06-16 | Sumitomo Pharmaceuticals Company, Limited | Improved controlled release formulation |
| DE3802996A1 (de) | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| EP0362526B1 (en) | 1988-08-23 | 1995-06-14 | Dana Farber Cancer Institute | The Alpha-subunit of the LFA-1 leukocyte adhesion receptor |
| EP0362531B1 (en) | 1988-09-01 | 1999-11-10 | Bayer Corporation | A human rhinovirus receptor protein that inhibits virus infectivity |
| AU4412889A (en) | 1988-09-28 | 1990-04-18 | Dana-Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
| US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| JPH04505009A (ja) | 1989-03-09 | 1992-09-03 | ダナ・ファーバー・キャンサー・インスティチュート | クローニングｌｆａ―１ |
| ZA903223B (en) | 1989-04-28 | 1991-02-27 | Baylor College Medicine | Dissemination of hiv-1 infected cells |
| CH679207A5 (enExample) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| WO1991019511A1 (en) | 1990-06-18 | 1991-12-26 | The General Hospital Corporation | CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5318965A (en) | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| AU8631991A (en) | 1990-08-27 | 1992-03-17 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
| JP2995860B2 (ja) | 1990-11-27 | 1999-12-27 | 味の素株式会社 | 新規ペプチド |
| US5288854A (en) | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| DE69229275T2 (de) | 1991-10-04 | 1999-12-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5298492A (en) | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| AU687755B2 (en) | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| AU5466794A (en) | 1992-11-18 | 1994-06-08 | Helsinki University Licensing Ltd Oy | Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| CA2150574A1 (en) | 1993-01-06 | 1994-07-21 | Shalaby W. Shalaby | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
| US5397791A (en) | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| ATE192430T1 (de) | 1993-12-03 | 2000-05-15 | Hoffmann La Roche | Essigsäurederivate als arzneimittel |
| US5470953A (en) | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| AU698406B2 (en) | 1994-04-19 | 1998-10-29 | University Of Kansas, The | ICAM-1/LFA-1 short-chain peptides and method of using same |
| US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5510495A (en) * | 1994-09-19 | 1996-04-23 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis |
| US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0710657B1 (de) | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| DE69731623D1 (de) | 1996-04-23 | 2004-12-23 | Ipsen Mfg Ireland Ltd | Saure Polymilchsäure Polymere |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT944619E (pt) | 1996-11-27 | 2007-01-31 | Bristol Myers Squibb Pharma Co | Novos antagonistas dos receptores da integrina |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
| DE69935133T2 (de) | 1998-03-27 | 2007-11-22 | Genentech, Inc., South San Francisco | Antagonisten zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| MXPA01005346A (es) | 1998-11-27 | 2003-03-27 | Kanji Takada | Una formulacion oral para suministro de farmaco gastrointestinal. |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| DK1140170T3 (da) | 1999-01-05 | 2006-10-23 | Univ Southern Australia | Antistoffragmenter til topisk behandling af öjensygdomme |
| AU2847200A (en) | 1999-01-27 | 2000-08-18 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| WO2000059477A1 (en) | 1999-03-31 | 2000-10-12 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| AU1186401A (en) | 1999-06-23 | 2001-01-22 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| HUP0203060A3 (en) | 1999-08-18 | 2003-11-28 | Sod Conseils Rech Applic | Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same |
| ECSP003707A (es) | 1999-10-13 | 2002-05-23 | Novartis Ag | Diazepanes |
| US6605597B1 (en) | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6294522B1 (en) | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| CN1409639A (zh) | 1999-12-14 | 2003-04-09 | 杰南技术公司 | 应用TNF－α拮抗剂和LFA－1拮抗剂治疗LFA－1或TNF－α介导的疾病 |
| JP2003519164A (ja) | 1999-12-31 | 2003-06-17 | ルトガーズ、ザ ステイト ユニバーシティ | ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤 |
| CA2395892C (en) | 1999-12-31 | 2014-06-03 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| US7521061B2 (en) | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| US20030064105A1 (en) | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| US6821986B2 (en) | 2000-05-05 | 2004-11-23 | Societe De Conseils De Recherchet Et E'applications Scientifiques (S.C.R.A.S.) | Amino acid derivatives and their use as medicines |
| GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| JP2004502681A (ja) | 2000-06-29 | 2004-01-29 | アボット・ラボラトリーズ | アリールフェニル複素環スルフィド誘導体および細胞接着を阻止する抗炎症性および免疫抑制性物質としてのその使用 |
| JP2002030052A (ja) * | 2000-07-18 | 2002-01-29 | Tosoh Corp | ヒドロキシアミノカルボン酸、その用途、及びその製造法 |
| EP1323702A4 (en) * | 2000-09-27 | 2005-12-07 | Asahi Glass Co Ltd | METHOD FOR THE PRODUCTION OF ACYL-FLUORIDES AND CARBOXYLIC ACID SALTS |
| PE20020420A1 (es) | 2000-10-02 | 2002-06-27 | Novartis Ag | Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1) |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| GB0028367D0 (en) | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| EP1347968A1 (en) | 2000-11-28 | 2003-10-01 | Genentech, Inc. | Lfa-1 antagonist compounds |
| WO2002050080A1 (en) | 2000-12-19 | 2002-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| CA2435415A1 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| ATE348829T1 (de) | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
| WO2002069904A2 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| US20020176841A1 (en) | 2001-03-19 | 2002-11-28 | Praecis Pharmaceuticals Inc. | Pharmaceutical formulations for sustained release |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| ES2296926T3 (es) | 2001-06-06 | 2008-05-01 | Aventis Pharma Limited | Tetrahidroisoquinolinas sustituidas para usar en el tratamiento de enfermedades inflamatorias. |
| CA2471096A1 (en) | 2001-12-19 | 2003-07-03 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| JP2005525374A (ja) | 2002-03-04 | 2005-08-25 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | 担体ペプチドを含有する持続放出ドラッグ製剤 |
| KR20050057175A (ko) | 2002-09-20 | 2005-06-16 | 알콘, 인코퍼레이티드 | 안구건조증 치료용 사이토카인 합성 저해제의 용도 |
| US7785578B2 (en) | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| RU2005117343A (ru) * | 2002-12-20 | 2006-01-27 | Астразенека Аб (Se) | Новые производные пиперидина в качестве модуляторов хемокинового рецептора ccr5 |
| WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| WO2005042710A1 (en) | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| PL1682537T3 (pl) | 2003-11-05 | 2012-09-28 | Sarcode Bioscience Inc | Modulatory adhezji komórkowej |
| GT200500139A (es) | 2004-06-08 | 2005-07-25 | Metodo para la preparacion de acidos hidroxamicos | |
| BRPI0610433A2 (pt) * | 2005-04-28 | 2010-11-23 | Wyeth Corp | forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada |
| CA2960117C (en) | 2005-05-17 | 2018-01-30 | Sarcode Bioscience Inc. | Lfa-1 antagonists for the treatment of eye disorders |
| WO2007057919A2 (en) * | 2005-10-25 | 2007-05-24 | Alembic Limited | An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine |
| JP4193895B2 (ja) | 2006-10-12 | 2008-12-10 | 横河電機株式会社 | 欠陥検査装置 |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| US8481730B2 (en) * | 2008-01-01 | 2013-07-09 | Cipla Limited | Method of synthesis of Bosentan, its polymorphic forms and its salts |
| WO2009139817A2 (en) * | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| WO2011050175A1 (en) * | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| WO2014018748A1 (en) | 2012-07-25 | 2014-01-30 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
-
2013
- 2013-07-25 WO PCT/US2013/052044 patent/WO2014018748A1/en not_active Ceased
- 2013-07-25 EP EP24169178.1A patent/EP4406950A3/en active Pending
- 2013-07-25 EP EP13823367.1A patent/EP2877465A4/en not_active Withdrawn
- 2013-07-25 KR KR1020207026445A patent/KR20200108932A/ko not_active Ceased
- 2013-07-25 SI SI201332083T patent/SI3715345T1/sl unknown
- 2013-07-25 KR KR1020157004283A patent/KR102157608B1/ko active Active
- 2013-07-25 RU RU2015102926A patent/RU2658015C2/ru active
- 2013-07-25 CN CN201380048592.8A patent/CN104797574B/zh active Active
- 2013-07-25 CN CN201911035155.8A patent/CN110922393A/zh active Pending
- 2013-07-25 JP JP2015524447A patent/JP6607780B2/ja active Active
- 2013-07-25 MX MX2015001098A patent/MX2015001098A/es active IP Right Grant
- 2013-07-25 CA CA2879982A patent/CA2879982C/en active Active
- 2013-07-25 EP EP20153723.0A patent/EP3715345B8/en active Active
- 2013-07-25 IN IN847DEN2015 patent/IN2015DN00847A/en unknown
- 2013-07-25 US US13/950,807 patent/US9085553B2/en active Active
- 2013-07-25 AU AU2013295706A patent/AU2013295706A1/en not_active Abandoned
- 2013-07-25 BR BR112015001608-1A patent/BR112015001608B1/pt active IP Right Grant
- 2013-07-25 HK HK15111648.6A patent/HK1210782A1/xx unknown
-
2015
- 2015-01-23 MX MX2020001602A patent/MX2020001602A/es unknown
- 2015-06-23 US US14/747,745 patent/US9708303B2/en active Active
-
2017
- 2017-06-13 US US15/621,141 patent/US10214517B2/en active Active
- 2017-11-22 AU AU2017265071A patent/AU2017265071B2/en active Active
-
2018
- 2018-07-19 JP JP2018135758A patent/JP2018162313A/ja active Pending
-
2019
- 2019-01-15 US US16/247,843 patent/US10906892B2/en active Active
- 2019-07-30 AU AU2019210525A patent/AU2019210525B2/en active Active
-
2020
- 2020-06-03 JP JP2020096854A patent/JP7008750B2/ja active Active
- 2020-12-02 AU AU2020281063A patent/AU2020281063A1/en not_active Abandoned
-
2023
- 2023-07-04 AU AU2023204287A patent/AU2023204287B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3715345T1 (sl) | Priprava zaviralca lfa-1 | |
| SMT201700094B (it) | Composto di pirazina carbossammide | |
| HUE036259T2 (hu) | Inhibitor vegyületek | |
| HUE037048T2 (hu) | Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására | |
| PT2878018T (pt) | Resumo | |
| LT2841428T (lt) | Dnr-pk inhibitoriai | |
| PT2819623T (pt) | Resumo | |
| EP2763896A4 (en) | UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS | |
| DK2859055T3 (da) | Polymercoatings | |
| DK2825087T3 (da) | Otoscanner | |
| EP2809145A4 (en) | CHLOROPLAST TRANSIT PEPTIDES | |
| DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
| EP2814472A4 (en) | DITHIOAMINE REDUCING AGENTS | |
| EP2824794A4 (en) | Charging cable | |
| EP2838564A4 (en) | HIGH-BRANCHED ALPHA-D-GLUCANE | |
| EP2805877A4 (en) | UNDER HOOD | |
| DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
| DE112012006109A5 (de) | Okklusionsschienenanordnung | |
| DK2854722T3 (da) | Stomipose | |
| PT2674413T (pt) | Resumo | |
| PT2831109T (pt) | Resumo | |
| EP2831482A4 (en) | Flange gasket | |
| EP2816694A4 (en) | FLAT CABLE WINDING DEVICE | |
| PT2825212T (pt) | Resumo | |
| DK2825157T3 (da) | Aminosyrelipider |